Amy Patick, Ph.D.
Amy Patick became interested in the field of Virology after completing an Honors research project at Wellesley College focusing on Rio Bravo Virus which she later found out was classified as a Biosafety Level 3 agent. She earned her PhD in Medical Microbiology from the University of Wisconsin, Madison and had postdoctoral training in the department of Immunology at the Mayo Clinic/Foundation in Rochester, MN focusing on herpesviruses and picornavirus, respectively. After completing her academic training, and thawing herself out after another cold MN winter, Amy "went over to the dark side” and joined Bristol-Myers Squibb as a Research Investigator in HIV research. She later tossed out her shovels and other snow moving tools, piled her animals and belongings into a rental van, and drove from Connecticut to San Diego, CA to join Agouron Pharmaceuticals (later on Pfizer Global Research and Development), where she worked from 1994 – 2007 in various leadership positions leading up to her role as Head of Antiviral Biology Therapeutic Area. In this capacity, Amy led the preclinical effort in the successful approval of Viracept (nelfinavir) for HIV infection. Most recently, Amy was Vice President, Biological Sciences at Genelabs Technologies and Vice President, Research at Adamas Pharmaceuticals. Amy is widely recognized as a leader in scientific and academic communities specializing in infectious disease drug discovery and clinical development activities. She is an Editorial Board member for several prestigious antiviral publications, has over 100 published abstracts/presentations and is a co-inventor on more than 20 patents. She recently served as the President of the International Society of Antiviral Research (the second woman in 26 years) and most recently has been working with various biotechnology companies as a pharmaceutical and scientific consultant. She credits the International Society of Antiviral Research for creating an annual forum to network with other scientists and to visit with cherished colleagues.Amy relocated to the Bay Area in CA four years ago and in her spare time she enjoys reading, yoga, organic gardening, hiking, backpacking and scuba diving.
Heather Greenstone, Ph.D.
Heather’s career in virology began in 1988 with her dialing a wrong number. She called the National Institutes of Health to inquire about a job vacancy for a technician position studying bacteria. The voice on the other end of the line didn’t know anything about that position, but thought another lab might have an opening—thus beginning what was to become a three-year commitment to the biochemical and ultrastructural study of bacteriophage, T4. Heather then began her pursuit of a PhD, as part of a collaborative program between Johns Hopkins University and the NIH. She performed her thesis work at the National Cancer Institute on a second generation prophylactic/therapeutic vaccine for human papillomavirus. As part of that effort, she contributed her experience in biochemistry and electron microscopy to the development of the now-licensed vaccine for cervical cancer. In 2003, following a five year post-doctoral fellowship (where she studied viral entry of herpesviruses, flaviviruses, and HIV), Heather joined the Virology Branch, in the National Institute of Allergy and Infectious Diseases. Heather now oversees multiple contracts devoted to antiviral testing in support of the scientific discovery and preclinical advancement of antivirals and vaccines.
Rhonda Cardin, Ph.D.
Rhonda became interested in herpesviruses as an undergraduate at Washington University in St. Louis when she learned that herpesviruses used many clever ways to outsmart their hosts. After receiving her A.B. in Biology and Psychology in 1983, she began her PhD studies at Tulane University in New Orleans, where she literally spent ‘hours in the dark’ working on how light and oxygen regulates bacteriochlorophyll synthesis in the photosynthetic bacterium, Rhodobacter capsulatus. After the lab moved to Louisiana State University in Baton Rouge, she received her PhD in Microbiology in 1989. While she was interviewing in the laboratory of Dr. Ed Mocarski, a leading cytomegalovirus (CMV) expert at Stanford University School of Medicine, she stayed at the ‘Hotel California’ in Palo Alto and agreed with The Eagles ‘that she would never leave’ and thus began her studies on CMV pathogenesis and latency. During her time at Stanford, she enjoyed San Francisco, wine country, the coast, and DJ’ing for the Stanford University Radio Station. In 1994, she moved to Memphis, TN to join the laboratory of Dr. Peter Doherty at St. Jude Children’s Research Hospital to study the immune response to gammaherpesviruses. While there, Dr. Doherty was awarded the 1996 Nobel Prize in Medicine for his pioneering research in immunology, thus making Peter the second most famous person in Memphis after Elvis! In 1998, she joined the pharmaceutical industry for evaluation of herpesvirus drugs but in 2003, she joined the Division of Infectious Diseases at Cincinnati Children’s Hospital Medical Center where her lab focuses on CMV pathogenesis and latency and evaluation of novel antivirals and vaccine strategies in CMV and HSV animal models. Ironically, Cincinnati is sometimes called the "San Francisco of the Midwest”!
Jennifer Moffat, Ph.D.Jennifer grew up in California and now lives in Upstate New York. Her academic journey across the country began at UC Davis where she studied biology. Her interest in microbiology took her to Stanford University to pursue a PhD about the intracellular bacterial pathogen Legionella pneumophila. During grad school she met and married Guy Moffat, a Silicon Valley engineer. They spent a fun 5 years mountain biking, sailboarding, skiing and wine tasting. When daughters arrived in 1995 and 1997, their activities focused on work and home. Jennifer was by then a postdoc in Pediatric infectious Diseases at Stanford Hospital. She discovered a passion for herpesviruses, particularly varicella zoster virus, which still captures her attention. While working with Ann Arvin, Jennifer developed the SCID-Hu mouse model for VZV replication that she continues to use for testing antiviral compounds in vivo. The outstanding SCID mouse facilities, and beautiful environment, at SUNY Upstate Medical University in Syracuse, NY, convinced her to move east in 1999. Both her lab and family have thrived in the land of long winters. Cross-country skiing is still a favorite pastime, and now rowing has been added to the family fun list. Jennifer rows with her masters crew team in boats of 8 or 4, and her daughters are on the high school varsity crew team. The abundant fresh water lakes, rivers, and canals of the region are ideal for the sport. To fuel her family’s appetite, Jennifer is an avid cook who finds most of her groceries at local farms and markets.
Karen always had a love for science but didn’t find her true calling until after graduating with a B.A. in biology from Hood College in Frederick, Maryland in 1996. Karen’s first job as a research technician at Southern Research Institute afforded her the opportunity to utilize her laboratory skills in a highly challenging and rewarding area of research that involved the prevention of the sexual transmission of HIV in women. Karen graduated with a MS in Biomedical Science from Hood College 10 years later in 2006, completing a thesis project which involved the selection and characterization of viruses resistant to a novel nonnucleoside RT inhibitor of HIV. During her tenure at Southern Research, and subsequently at TherImmune Research Corporation, Karen’s primary responsibilities involved managing and providing technical assistance to the development of topical microbicides as HIV prevention agents and was highly involved in defining the testing algorithms required for successful preclinical and IND-directed development of these products. In 2004, Karen was one of the founding members of ImQuest BioSciences where she has been Director of Topical Microbicide and STI Research. In addition to HIV prevention programs, Karen’s interests have extended into other areas of women’s health, and she has been instrumental in leading ImQuest’s CRO-based efforts into these new and important areas of infectious disease, cancer, and inflammatory disease. Karen dreams that the HIV microbicide agent that she has been working with since the late 1990’s will enter human clinical trials in 2013 and eventually become a microbicide that will impact women’s health. In 2011 Karen married her husband Bob, who she has worked with since 1996. Believe it or not, it works! In her spare time Karen enjoys spending time with her husband and golden retriever Bella, wine tasting, traveling to warm, sunny locations, and snorkeling. She would love to one day be on the Amazing Race with her husband!
Anneke K Raney, Ph.D.
Anneke is currently a Senior Research Scientist and Project Team Leader at Gilead Sciences in the HBV Cure Discovery Virology Group. She leads antiviral projects in the company’s efforts to cure, rather than control, the chronic HBV infection of 350 million people. She began her HBV research at The Scripps Research Institute, and she later obtained a PhD studying the transcriptional regulation of HBV. Her transition from academia to industry in 2001 allowed her to continue working on HBV at ICN/Valeant Pharmaceuticals, but with the new challenge to discover and develop antiviral therapies for the treatment of chronic HBV infection. The opportunities to lead drug discovery and pre-clinical development programs and to support clinical programs for HCV and HIV while at Valeant and Ardea Biosciences broadened Anneke’s virus expertise and provided valuable perspective on antiviral drug development. She is excited to return to HBV, working with many talented scientists exploring new approaches to cure chronic HBV infection. The move to Gilead brought Anneke to Northern California from the (relatively) warm waters of San Diego, where she was an enthusiastic swimmer of La Jolla Cove and a SCUBA diver in the same spectacular setting. San Francisco’s Aquatic Park and Monterey Bay provide chillier, but beautiful alternatives. When she wants to stay dry, hiking in the Half Moon Bay and Lake Tahoe areas, listening to live music, and reading keep Anneke amused.
Graciela Andrei, Ph.D.
Graciela Andrei was born in Buenos Aires, Argentina, from an Italian family. She studied Biology at the Faculty of Sciences, University of Buenos Aires. Before finishing her studies, she started working ad honorem at the Laboratory of Virology and she was definitively contaminated with the ‘research virus’. She then started a PhD thanks to a scholarship from the National Research Council. She did her thesis on antivirals under guidance of Celia Coto and Ramon De Torres. By the end of her doctoral thesis, Erik De Clercq attended a meeting in Mar del Plata, a city at the seaside in Argentina, and he accepted Graciela for 1-2 years as a post-doc at the Rega Institute for Medical Research. In February 1989, Graciela moved to the other side of the world and arrived to Leuven and started a long journey at the KU Leuven, one of the oldest universities in Europe. She begun working with Robert Snoeck on cytomegalovirus and they progressively enlarged the spectrum of DNA viruses studied. They have a very fruitful and complementary collaboration since 1989 at the Laboratory of Virology and Chemotherapy (Department of Microbiology and Immunology), nowadays directed by Jan Balzarini. In 2003, Robert became her husband and they always kept the rule ‘do not mix private live with work’ and they succeeded in making it work. Graciela became an Assistant Professor at the Faculty of Medicine, KU Leuven, Belgium in 2005. Her research work is mainly focused on chemotherapy of viral diseases, with emphasis on herpes-, pox-, polyoma- and papillomaviruses, and the study of the molecular mechanisms underlying antiviral drug-resistance and anticancer activity of nucleotide analogues. She has been a member of ISAR since 1989 and she is the present Secretary of the International Society for Antiviral Research. Besides, her passion for research, she enjoys reading, traveling, gardening (they have a 3 acres of vegetable garden), cooking (she is an expert of home-made jams and pâté, among several specialties) and DIY (do-it-yourself). But most of all, she cares for Clio, a lovely and beautiful golden retriever that gives Graciela and Robert a lot of joy and fun.
Kara Carter, Ph.D.
grew up in sunny Southern California and first fell in love with viruses while
an undergraduate at Stanford University.
There she became an advisee of Robert Seigel whose "Humans and Viruses”
class led to a long-standing fascination with viruses. While at Stanford, she conducted research in
the laboratory of Drs. Charles Prober and Ann Arvin, generating a cell line
expressing glycoprotein G of herpes simplex 2 used to differentiate antibodies
to HSV1 and HSV2. Following her interest
in herpes virology, Kara did her graduate work in the laboratory of Dr. Bernard
Roizman at the University of Chicago, identifying and studying novel
transcripts from HSV1 and their role in the viral replication cycle. While at U of C, Kara met and married a
fellow lab mate, Charley Carter, and together they have supported each other’s
careers. From Chicago, Kara and Charley
moved to Boston where Kara did a fellowship in the laboratory of Dr. Elliott
Kieff at Harvard University studying EBV induced transformation of primary
human B cells, being one of the first to apply the new technique of
transcriptional profiling to characterize these cell lines and the
transcriptional changes associated with the transformation process. During that time, Kara also beta tested some
of the first real-time PCR machines. During
her post-doc years, Kara and Charley added two beautiful boys to their
family. After her academic career, she
went on to the biotech/pharmaceutical industry, where she led drug discovery
groups and several small molecule projects focused on virology, immunology and
oncology. Currently, Kara is Head of
Antiviral Research for Sanofi.
Ann D. Kwong Ph.D.
Ann D Kwong is an industry leader in antiviral drug discovery with more than 20 years’ experience in developing successful drug candidates. Ann created the Infectious Diseases group at Vertex Pharmaceuticals. Her group played a leading role in the research, development, and commercialization of telaprevir (INCIVEK™), a HCV protease inhibitor with the best drug launch in history (over $1B in sales in < 1 year). Ann also started the influenza virus program, which led to the development of VX-787, which recently showed antiviral activity in a Phase 2 virus challenge study. Previously, Ann worked on HSV and HCV antiviral drug discovery at Schering Plough Research Institute and helped to solve the crystal structure of HCV helicase. She is a founding member of HCV DRAG (HCV Drug Development Advisory Group), a consortium of industry leaders, clinical trial leaders, community representatives, and FDA and EMA regulators who work together to optimize HCV drug development.
During her time in industry, Ann became convinced that one reason for the poor success rate of pharma companies is outmoded discovery and development models and standards, perpetuated by risk-averse systems. In response, Ann developed the concept of InnovaTID, which stands for InnovativeThinking for Innovative Drugs and started two organizations: i) InnovaTID Pharmaceuticals, INC (InnovaTID) is focused on creating antiviral and antibacterial drugs for areas of high unmet medical need, especially in areas where the market value is too small for a bigger pharmaceutical company. ii) The InnovaTID Institute for Drug Creation is a not-for-profit organization whose aim is to teach pharmaceutical industry scientists and professionals how to create and utilize a more effective drug creation process using a case study/master class format.
Ann got into virology by accident, when she sat in on an undergraduate virology class taught by Niza Frenkel and Bernard Roizman, and ended up with a PhD in virology from the University of Chicago. Growing up outside Chicago in a swamp, catching butterflies and frogs and playing the viola, Ann didn’t like classroom science or math classes, nor do really well in them. She and her scientist wife, Dasa Lipovsek, have 4 black German shepherd dogs and two Lusitano dressage horses. Ann is most proud of her daughter, Ursula Kwong-Brown, who is a neurobiologist and a composer. Her favorite memory is driving from Boston to Berkeley, CA with Ursula and a dog, stopping at A&W Root Beer stands and collecting rocks and fossils along the way.
Dr. Katherine Seley-Radtke Ph.D.
Dr. Katherine Seley-Radtke is a Professor in the Department of Chemistry and Biochemistry at the University of Maryland, Baltimore County (UMBC). She earned her Ph.D. in Organic Chemistry from Auburn University, and continued her postdoctoral research at Auburn for two years before joining the faculty at Georgia Tech in 1998. In 2003 she moved her research group to UMBC where her current research involves a chemical biology approach to nucleoside and heterocyclic drug discovery and development with a therapeutic emphasis on antiviral, anticancer, and antiparasitic targets. Some of her more notable scientific "hats" currently include serving as an ISAR board member and Chair of the Poster Awards Committee, as the Vice President (and President-elect) for the International Society of Nucleosides, Nucleotides and Nucleic Acids (IS3NA), as a standing member of the NIH AIDS Drug Discover and Development (ADDT) study section, a member of the American Chemical Society Medicinal Chemistry Division Awards Committee, and an associate Editor for Current Protocols in Chemical Biology. Kathie is also one of the co-organizers of this year's National Medicinal Chemistry Symposium to be held in Charleston, SC immediately after ICAR. Kathie also spends time each year in Russia as part of her National Academies of Science Jefferson Science Fellowship commitment. Kathie's husband Mike is a Scientific Review Officer at NIH (and a long time attendee of ICAR). They enjoy their three dogs (including Rioja, a 240-ish lb. Spanish Mastiff who thinks he's a lap dog!), cooking, good wines, traveling to new and interesting places, and their three beautiful granddaughters (7, 4 and 1.5 years old) who live in San Marcos, CA.